<DOC>
	<DOC>NCT00638456</DOC>
	<brief_summary>This study is designed to evaluate whether or not oral viscous budesonide is effective in treating children with Eosinophilic Esophagitis.</brief_summary>
	<brief_title>Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Histologic evidence of EE defined as greater than 20 eosinophils per hpf on esophageal biopsy Ages 1 yrs and older Ability to continue the same diet that the patient was on at the time of EGD with biopsy Adverse reaction or allergy to budesonide Pregnancy Chronic diseases requiring immunomodulatory therapy Use of swallowed topical corticosteroids for EE within the past 3 months Use of systemic steroids 2 months prior to study entry Upper gastrointestinal bleed within 4 months of study entry Chronic use of medications that predispose to upper gastrointestinal bleeding including nonsteroidal antiinflammatory medications or anticoagulants Evidence of adrenal suppression prior to study entry Evidence of concurrent eosinophilic gastritis, enteritis, colitis, or proctitis Recent changes in asthma or allergic rhinitis therapy for 3 months</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Eosinophils</keyword>
	<keyword>Esophagitis</keyword>
	<keyword>Microscopy</keyword>
</DOC>